81 related articles for article (PubMed ID: 24473897)
21. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
[TBL] [Abstract][Full Text] [Related]
22. Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment.
Kagan RM; Cheung PK; Huard TK; Lewinski MA
Antiviral Res; 2006 Aug; 71(1):42-52. PubMed ID: 16600392
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
[TBL] [Abstract][Full Text] [Related]
24. Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.
Song W; Maeda Y; Tenpaku A; Harada S; Yusa K
Antiviral Res; 2004 Mar; 61(3):173-80. PubMed ID: 15168798
[TBL] [Abstract][Full Text] [Related]
25. Luminescent quantum dots fluorescence resonance energy transfer-based probes for enzymatic activity and enzyme inhibitors.
Shi L; Rosenzweig N; Rosenzweig Z
Anal Chem; 2007 Jan; 79(1):208-14. PubMed ID: 17194141
[TBL] [Abstract][Full Text] [Related]
26. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
[TBL] [Abstract][Full Text] [Related]
27. Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
Dewdney TG; Wang Y; Liu Z; Sharma SK; Reiter SJ; Brunzelle JS; Kovari IA; Woster PM; Kovari LC
Bioorg Med Chem; 2013 Dec; 21(23):7430-4. PubMed ID: 24128815
[TBL] [Abstract][Full Text] [Related]
28. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
[TBL] [Abstract][Full Text] [Related]
29. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
[TBL] [Abstract][Full Text] [Related]
30. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
31. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
Martinez-Cajas JL; Wainberg MA; Oliveira M; Asahchop EL; Doualla-Bell F; Lisovsky I; Moisi D; Mendelson E; Grossman Z; Brenner BG
J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
[TBL] [Abstract][Full Text] [Related]
32. Nanoscale flow cytometry reveals interpatient variability in HIV protease activity that correlates with viral infectivity and identifies drug-resistant viruses.
Bonar MM; Tabler CO; Haqqani AA; Lapointe LE; Galiatsos JA; Joussef-Piña S; Quiñones-Mateu ME; Tilton JC
Sci Rep; 2020 Oct; 10(1):18101. PubMed ID: 33093566
[TBL] [Abstract][Full Text] [Related]
33. HIV-2 Protease resistance defined in yeast cells.
M'Barek NB; Audoly G; Raoult D; Gluschankof P
Retrovirology; 2006 Sep; 3():58. PubMed ID: 16956392
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of probe signal for screening of HIV-1 protease inhibitors in living cells.
Yao H; Jin S
Sensors (Basel); 2012 Dec; 12(12):16759-70. PubMed ID: 23223077
[TBL] [Abstract][Full Text] [Related]
35. Quantum dot-based concentric FRET configuration for the parallel detection of protease activity and concentration.
Wu M; Petryayeva E; Algar WR
Anal Chem; 2014 Nov; 86(22):11181-8. PubMed ID: 25361050
[TBL] [Abstract][Full Text] [Related]
36. Development of A Fission Yeast Cell-Based Platform for High Throughput Screening of HIV-1 Protease Inhibitors.
Benko Z; Zhang J; Zhao RY
Curr HIV Res; 2019; 17(6):429-440. PubMed ID: 31782368
[TBL] [Abstract][Full Text] [Related]
37. Effects of plant extracts on HIV-1 protease.
Filho JR; de Sousa Falcão H; Batista LM; Filho JM; Piuvezam MR
Curr HIV Res; 2010 Oct; 8(7):531-44. PubMed ID: 20946094
[TBL] [Abstract][Full Text] [Related]
38. A rapid and sensitive bacterial assay to determine the inhibitory effect of 'interface' peptides on HIV-1 protease co-expressed in Escherichia coli.
Ast O; Jentsch KD; Schramm HJ; Hunsmann G; Lüke W; Petry H
J Virol Methods; 1998 Mar; 71(1):77-85. PubMed ID: 9628224
[TBL] [Abstract][Full Text] [Related]
39. Selective and facile assay of human immunodeficiency virus protease activity by a novel fluorogenic reaction.
Yu Z; Kabashima T; Tang C; Shibata T; Kitazato K; Kobayashi N; Lee MK; Kai M
Anal Biochem; 2010 Feb; 397(2):197-201. PubMed ID: 19852926
[TBL] [Abstract][Full Text] [Related]
40. Probe detects HIV protease and toxicity of drugs.
AIDS Patient Care STDS; 2010 Nov; 24(11):744. PubMed ID: 21067358
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
